BANK VONTOBEL/CALL/MODERNA/140/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 19:03:05 18/06/2024 BST | ||
| 0.082 EUR | -70.71% |
|
| Current month | -65.43% | ||
| 1 month | -39.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 18/06/24 | 0.082 | -70.71% |
| 17/06/24 | 0.28 | +3.70% |
| 14/06/24 | 0.27 | -64.00% |
| 13/06/24 | 0.75 | -23.47% |
| 12/06/24 | 0.98 | +4.26% |
Delayed Quote Deutsche Boerse AG
Last update June 18, 2024 at 07:03 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VM3MYW |
| ISIN | DE000VM3MYW1 |
| Date issued | 06/10/2023 |
| Strike | 140 $ |
| Maturity | 21/06/2024 (3 Days) |
| Parity | 10 : 1 |
| Emission price | 0.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.82 € |
|---|---|
| Lowest since issue | 0.059 € |
| Spread | 0.013 € |
| Spread % | 14.13% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.9
USD
Average target price
145.2
USD
Spread / Average Target
+5.31%
- Stock Market
- Warrants
- Warrant
